Erik J. Tillman
- Aging top 5%
-
- Diet, Metabolism, and Disease 3
- Epidemiology top 5%
- Liver Disease Diagnosis and Treatment 8
- Hepatology top 5%
- Molecular Biology top 10%
- Fibroblast Growth Factor Research 10
- Kruppel-like factors research 7
- Chromatin Remodeling and Cancer 4
- Epigenetics and DNA Methylation 3
- Genomics, phytochemicals, and oxidative stress 2
-
- Cancer Mechanisms and Therapy 3
Erik J. Tillman
20 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 83
- Aging 52
- Endocrinology, Diabetes and Metabolism 301
- Epidemiology 586
- Hepatology 134
- Molecular Biology 835
Countries citing papers authored by Erik J. Tillman
This map shows the geographic impact of Erik J. Tillman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik J. Tillman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik J. Tillman more than expected).
Fields of papers citing papers by Erik J. Tillman
This network shows the impact of papers produced by Erik J. Tillman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik J. Tillman. The network helps show where Erik J. Tillman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Erik J. Tillman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 5 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 37 | |
| 4 | 2023 | 6 | |
| 5 | Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialbreakdown → | 2023 | 146 |
| 6 | 2022 | 72 | |
| 7 | Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trialbreakdown → | 2021 | 255 |
| 8 | 2021 | 11 | |
| 9 | 2021 | 1 | |
| 10 | 2020 | 102 | |
| 11 | 2020 | 151 | |
| 12 | 2019 | 43 | |
| 13 | 2018 | 12 | |
| 14 | 2014 | 96 | |
| 15 | 2014 | 49 | |
| 16 | 2013 | 57 | |
| 17 | 2013 | 136 | |
| 18 | 2012 | 18 | |
| 19 | 2011 | 1 | |
| 20 | 2006 | 184 |
About Erik J. Tillman
Erik J. Tillman is a scholar working on Aging, Molecular Biology and Hepatology, having authored 21 papers that have together received 1.4k indexed citations. Recurring topics across this work include Fibroblast Growth Factor Research (10 papers), Liver Disease Diagnosis and Treatment (8 papers), Kruppel-like factors research (7 papers), Chromatin Remodeling and Cancer (4 papers), Cancer Mechanisms and Therapy (3 papers), Epigenetics and DNA Methylation (3 papers), Diet, Metabolism, and Disease (3 papers) and Genomics, phytochemicals, and oxidative stress (2 papers). The work is most often cited by research in Aging (52 citations), Endocrinology, Diabetes and Metabolism (301 citations) and Epidemiology (586 citations). Erik J. Tillman has collaborated with scholars based in United States, United Kingdom and Tunisia. Frequent co-authors include Tim Rolph, Brittany de Temple, Guy Neff, Andrew Cheng, Kitty Yale, Stephen A. Harrison, Cynthia Behling, Erica Fong, Rashmee Patil and Chen Hu. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Medicine, Diabetes, PLoS Genetics and Cell Reports Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.